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Long-Term Oral Contraceptive Use and Incidence of Breast Cancer 
Abstract 
Breast cancer is the most frequent occurring malignancy in American women and the 
second leading cause of cancer deaths (Lovett et al., 2017). Combination oral contraceptives 
(OCs) are taken by more than 100 million women worldwide making them the most commonly 
used birth control method (Stewart & Black, 2015). The use of OCs has been well studied in 
relation to breast cancer risk, however the impact of its use in relation to breast cancer risk has 
been inconsistent (Smith, Brinton, Kramer, Jemal, DeSantis, 2011).  
A 31-year-old woman, N.S., with no current concerns presented to establish care. She 
was a healthy appearing woman of stated age, with no known medical comorbidities, who has 
used long-term (>10 years) OCs for birth control. Upon further inquiry, her family medical 
history is significant for breast and ovarian cancers. Her mother developed breast cancer in her 
40s and is deceased. The patient was unsure if her mother had completed genetic testing and had 
not visited with a genetic counselor nor initiated genetic testing. This case illustrates the potential 
relationship of breast cancer with long-term use of OCs, especially in high-risk women.  
A literature review was completed to determine the incidence of breast cancer with long- 
term use of OCs. The databases of CINAHL (Cumulative Index of Nursing and Allied Health 
Literature), PubMed, and ClinicalKey were utilized to search the literature. Results were limited 
to the past five years, with a total of 1,059 results. After a thorough literature review was 
conducted, eight articles were deemed relevant to the clinical question. A thorough discussion of 
findings is discussed in the literature review section.  
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Background 
The average age of women at their first birth continues to rise over the past four decades, 
with women in their 30s having more children as compared to those in their 20s (Caplan-Bricker, 
2017; Sifferlin, 2014). Therefore, there is a potential for an increase in the duration of OC use. 
Since its first introduction in the United States in the 1950s, several different forms of birth 
control are available today with an estimated 100-150 million women using OCs (Iverson, 
Sivasubramaniam, Lee, Fielding, Hannaford, 2017). A variety of reasons may necessitate the use 
of OCs including: birth control, menstrual pain, menstrual regulation, acne, and/or 
endometriosis, with the highest percentage of women using OCs for birth control (95%) 
(Guttmacher Institute, 2018). 
The prevalence of breast cancer today has led to large public health burden, prompting 
further investigation into this phenomenon. Naturally occurring estrogen and progesterone have 
been shown to influence the development of certain breast cancers (National Cancer Institute, 
2012). Since the introduction of OCs, the amount of estrogen and progesterone has decreased, 
however breast cancer continues to remain the second leading cause of death in women (Lovett 
et al., 2017). A multitude of confounding factors other than exogenous estrogen and progesterone 
exposure may contribute to this finding including environmental and dietary factors, advancing 
age, and longer duration of exposure to endogenous estrogen influenced by lower parity (Lovett 
et al., 2017).  
As presented, N.S. is a nulliparous 31-year-old-women with a history of OC use and a 
significant family history of malignancy, including breast and ovarian carcinomas. The 
relationship between OC use and breast cancer incidence has been studied; however, results have 
been largely inconsistent (National Cancer Institute, 2012). As women continue to utilize OCs 
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for a longer duration of time, the purpose of this paper is to determine if a relationship exists 
between long-term OC use and the incidence of breast cancer.  
Case Report 
N.S., a 31-year-old single, nulliparous Caucasian woman without significant medical 
history, presented to establish care. She had routine care with a previous physician and denies 
any questions or concerns today. She has been using long-term OCs, unsure of the name, for 
birth control. She is in a monogamous relationship and desires to have a family in the future. She 
takes a multivitamin occasionally and denies use of herbs/supplements. She has an allergy to 
penicillin (hives) that occurred when she was young. Surgical history is significant for an 
appendectomy when she was young. Her immunizations are up-to-date per current CDC (Center 
for Disease Control and Prevention) recommendations. She is a grade-school teacher in the 
community. She exercises approximately once per week, and typically follows a healthy diet. 
Her family history is significant for breast cancer in her mother, maternal aunt, and 
cousin. Her mother acquired breast cancer in her 40s and is deceased; she does not know if 
genetic testing was completed. Her father is adopted, without significant medical history, and 
with unknown family history. Her brother is without significant medical history. 
Her physical exam is without abnormal findings. She declined a full physical exam and 
does not perform regular self-breast examinations. No lab tests or imaging were indicated. She 
was agreeable to return for a well-woman appointment and examination. Given her strong family 
history of breast cancer, we discussed the importance of visiting with a genetic counselor and/or 
receiving genetic testing. She was agreeable to this treatment plan and plan-of-care will be 
modified based on genetic results, if obtained (see Appendix A). 
Literature Review 
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 A thorough literature review was conducted to determine the incidence of breast cancer 
and long-term use of OCs. An online literature search was conducted using the Harley E. French 
Library at the University of North Dakota to find supportive evidence for the PICOT question: 
how does the use of long-term (> 10 years) of OC use, as compared with short-term or no use, 
affect the incidence of breast cancer? Several databases were utilized to compile a thorough 
review of the literature. Initial databases utilized were CINAHL and PubMed as they are 
considered essential databases for the health sciences (Mateo & Foreman, 2014). Additionally, 
the database ClinicalKey was utilized to include Elsevier’s medical and surgical journals. Based 
on the clinical question, the search focused on the terms long-term OCs and breast cancer. 
The literature search was first conducted utilizing the CINAHL database. According to 
Mateo and Foreman (2014), CINAHL is a “comprehensive source for nursing and allied health 
journals” with over 5,000 journals available (p. 23). The literature search was conducted using 
the CINAHL headings “long term oral contraceptives” and “breast cancer.” Results were filtered 
to the English language, human subject, and publication with five years resulting in seven 
articles. One article was deemed relevant to the clinical question.  
The next database utilized was PubMed. According to Mateo & Foreman (2014), 
PubMed is the ideal choice for initial searches and is the largest biomedical database. The 
literature search was conducted using the medical subject heading (MeSH) terms of “long term 
oral contraceptives” and “breast cancer.” Results were filtered to the human subject and 
publication within five years resulting in 22 articles. Two articles were deemed relevant to the 
clinical question; however, one article was a duplicate of a study previously found and was not 
included for review. 
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Lastly, the database of ClinicalKey was utilized to further substantiate the literature 
review. The literature search was conducted utilizing the following keywords “long term oral 
contraceptive use” and “breast cancer.” Results were filtered to include randomized control 
trials, meta-analyses, systematic reviews, books, clinical trials, and publication within the past 
five years. This resulted in 147 results, of which five articles were deemed relevant to the clinical 
question. One of the five articles included duplicate information from a previous study, and lead 
to findings of an alternate study that was retrieved utilizing PubMed and included for review.  
A brief search for grey literature was conducted to reduce publication bias. The search 
engine of Google was utilized to look for unpublished studies and conference proceedings using 
the keywords “long term oral contraceptives” and “breast cancer.” No ongoing studies were 
identified; however, one newspaper article was deemed relevant, but was a duplicate of a study 
previously found and was not included for review. After the literature search was completed, 
eight articles were deemed relevant to the clinical question. It is important to note, the brand and 
strength of OC utilized throughout the studies were reported in two of the eight articles included 
for review, and another study classified OC estrogen content as low, medium, or high. Studies 
utilized did not include women defined as high-risk for development of breast cancer. 
Summary of Findings 
Levels of evidence included in the literature review range from level I-V with: one study 
compromising level I evidence (Zhu, Lei, Feng, & Weng, 2012), one level II evidence (Freund, 
Kelsberg, & Safranek, 3014), four level III evidence (Morch et al., 2017; Iversen, 
Sivasubramaniam, Lee, Fielding, & Hannaford, 2017; Aronson, 2016; Beaber et al., 2014), and 
two level V evidence (Smith, Brinton, Kramer, Jemal, & DeSantis, 2017; Bhupathiraju et al., 
2016) . Studies reviewed showed inconsistent findings from no elevation in risk to a 50 percent 
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increased risk. Of the three studies that identified a positive correlation between long-term OC 
use and breast cancer development: risk increased from 1.09 (95% CI, 0.96 to 1.23) with less 
than one year of use to 1.38 (95% CI, 1.26 to 1.51) with more than ten years of use (P=0.002), 
and for every ten-years’ increment of OC use, risk increased to 14% (95% CI, 1.05-1.23) (Mørch 
et al., 2017; Zhu et al., 2012). Additionally, current and recent users were found to be at an 
increased risk of developing breast cancer regardless of duration of use (RR, 1.24; 95% CI, 1.15 
to 1.33) (Smith et al., 2017). It should be noted however, the increased risk associated with 
recent use subsided within ten years of cessation of OC use; therefore, the risk associated with 
long-term use may primarily be due to recent usage (Smith et al., 2017). 
Three of the eight studies did not find a statistically significant correlation between long-
term OC use and development of breast cancer (Aronson, 2016; Freund et al., 2014; Iversen et 
al., 2017). A systematic review conducted by Freund et al., (2014), “found no significant 
difference in breast cancer risk between OCP uses and nonusers, regardless of age or duration of 
use” (p. 548). Similar results were found by Aronson (2016). Neither recent OC use (<10 years, 
RR=0.77; 95% CI, 0.54-1.11) nor past OC use (>10 years, RR=1.01; 95% CI, 0.80-1.28) affected 
risk of developing breast cancer (Freund et al., 2014).  
Similarly, a prospective cohort study conducted by Iversen et al., (2017), observed 
women for 44 years. There was no evidence of new cancer risks appearing later in life among 
women who had used OCs. It should be noted, the mean duration of OC use was approximately 
three years, however this study was still included as incidence of cancer was followed for 44 
years. Additionally, the study also concluded the increased risk of breast cancer seen with current 
and recent users appears to be lost within approximately five tears of stopping OC (Iversen et al., 
2017).  
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Lastly, two of the eight studies founded mixed results. Lifetime duration of OC use 
greater than or equal to 15 years was associated with a 50 percent increased breast cancer risk 
(OR=1.5, 95% CI, 1.1-2.2) however, this risk was not found among women with less than 15 
years of lifetime OC use (Beaber et al., 2014). Bhupathiraju et al. (2016), concluded the use of 
OC for ten or more years, and past OC use before a first full-term pregnancy, did not 
significantly increase the risk of breast cancer. However, duration of use for greater than ten 
years was associated with a higher risk of death from breast cancer (HR=1.39; 95% CI, 1.13-
1.71) (Bhupathiraju et al., 2016).  
Learning Points 
• There are inconclusive results comparing long-term OC use and the incidence of 
breast cancer. 
• Studies reviewed showed inconsistent findings from no elevation in risk to a 50 
percent increased risk. 
• Several studies correlated an increased risk of breast cancer development with 
current and recent OC use. Future studies are needed to further quantify and 
demonstrate this effect.  
• Two of the eight studies included for review differentiated between brand and 
strength of OC formulation utilized. One study included noted OC estrogen 
strength as low, moderate, or high. The remaining five studies did not 
differentiate between formulations of OC utilized, nor if users had only utilized 
one preparation for ten years or longer. Future studies are needed to determine the 
potential effects.  
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• Clinical recommendations for the use of OCs use should include an informed 
discussion between the provider and the patient about the inconsistent correlation 
between the use of long-term OCs and the development of breast cancer.  
• The strongest study included for review was a meta-analysis conducted by Zhu et 
al. (2012), demonstrating a statistically significant correlation between OC use 
and development of breast cancer for every ten-years increment of use (14%: 95% 
CI, 1.05-1.23). 
Breast cancer is the second leading cause of death in women (Lovett et al., 2017). As 
women continue to have their first child at a later age, the potential for OC use throughout a 
lifetime has increased in duration (Caplan-Bricker, 2017). More than 100 million women in the 
United States utilize OCs making them the most commonly utilized birth control method 
(Stewart & Black, 2015). This paper has demonstrated the inconsistent correlations found 
between the use of OCs for greater than ten years duration and the development of breast cancer. 
Further studies are warranted to continue to monitor these effects. Clinical recommendations for 
the use of OCs should included an informed conversation between the provider and patient about 
the inconsistent correlation between the use of long-term OCs and the development of breast 
cancer.  
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CC:  Establish Care 
HPI: N.S. is a 31-year-old, single female here to establish care. She has just moved from Fargo 
and is grade-school teacher. She had routine care with a previous physician and a release of 
information form will be signed. She states she is currently healthy and does not have any 
questions or concerns today.  
PMH: None 
Surgical: Appendectomy when young, does not remember date. 
Allergies: Penicillin-rash when young. 
Immunizations: Up to date per current CDC recommendations. Has received influenza vaccine 
for this season. 
Current medications: Oral Contraceptive daily (does not remember the name). OTC 
multivitamin occasionally.  
FH: Mother-deceased: breast cancer (40s). Does not know if she had genetic testing completed. 
Father-alive: adopted, unknown family history. Brother-alive: healthy. Maternal Grandmother-
deceased: ovarian cancer. Maternal Aunt-alive: breast cancer. Cousin-alive: breast cancer. 
SH: School grade teacher. Exercises approximately once per week. Tries to follow a healthy 
diet. In a monogamous relationship with boyfriend. Desires to have a family in the future. 
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ROS:  
Constitutional: Denies fevers, unintentional weight loss, chills or night sweats.  
Neuro: Denies headaches, double vision. 
Cardiac: Denies chest pain, shortness of breath. 
GI/GU: Denies constipation, diarrhea, urinary frequency, hesitancy, or blood in 
urine/stool. 
Musculoskeletal: Denies myalgias or pain. 
Objective 
Vitals: BP 110/66, P 82, R 14, Weight 155 lbs. Denies pain. 
PE: General: Alert, in no acute distress. Well nourished. 
Head: Normocephalic, atraumatic. Upright, midline, without tics or tremors. 
Ears: The external auditory canals are clear. Tympanic membranes are translucent, grey, bony 
landmarks noted. 
Throat: Pink, moist, without lesions or tonsillar exudate. 
Neck: Supple without lymphadenopathy. Thyroid without nodules.  
Lymph nodes: No adenopathy noted.  
Lungs: Clear to auscultation without vesicular sounds. 
Heart: Regular rate and rhythm. S1 and S2. No murmurs present.  
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Musculoskeletal: Gait appropriate. Strength symmetrical without weakness. Back without 
curvature. 
Labs/Diagnostics: None indicated. 
Assessment 
31-year-old presenting to establish care. 
ICD 10: Z00.00 Encounter for general adult examination 
  Z80.3 Family history of malignant neoplasm of breast 
CPT 10: 99204 New patient, comprehensive patient examination 
Plan 
1. Patient agreeable to visit with genetic counselor given family history of breast and 
ovarian cancer. Plan of care will be modified based on genetic results. Referral placed. 
2. Patient to schedule appointment for well-women exam to obtain labs and complete 
physical examination. 
3. Continue to get 150 minutes of moderate activity per week and follow a heart healthy 
diet. 
4. Follow-up as needed. Call with any questions or concerns.  
 
